Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Grace Therapeutics Inc GRCE

Healthcare Biotechnology
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company’s lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to improve neurological symptoms of Ataxia-Telangiectasia (A-T) and GTX-101, a... see more

Current News (NDAQ:GRCE)

Grace Therapeutics to Participate in 16th Annual Craig-Hallum Alpha Select Conference

GlobeNewswire November 17, 2025

Grace Therapeutics Announces Second Quarter 2026 Financial Results, Provides Business Update

GlobeNewswire November 13, 2025

Grace Therapeutics Announces Abstract Accepted for Presentation at Society of Vascular and Interventional Neurology Annual Meeting

GlobeNewswire November 11, 2025

Grace Therapeutics Secures Approximately $4.0 Million through Common Warrant Exercises Following Acceptance of New Drug Application for GTx-104 for formal FDA Review

GlobeNewswire October 23, 2025

Grace Therapeutics Pivotal Phase 3 STRIVE-ON Safety Trial Presented at 2025 Neurocritical Care Annual Meeting

GlobeNewswire September 22, 2025

Grace Therapeutics Granted Sixth U.S. Patent Covering I.V. Dosing Regimen for GTx-104

GlobeNewswire September 18, 2025

Grace Therapeutics Announces Presentation at The H.C. Wainwright 27th Annual Global Investment Conference

GlobeNewswire September 4, 2025

Grace Therapeutics Announces U.S. Food and Drug Administration Acceptance for Review of New Drug Application for GTx-104

GlobeNewswire August 27, 2025

Grace Therapeutics Announces First Quarter 2026 Financial Results, Provides Business Update

GlobeNewswire August 12, 2025
View More News ››

Opinion & Analysis (NDAQ:GRCE)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:GRCE)

Acasti Pharma (NASDAQ:ACST): A Promising Specialty Pharmaceu

http://beyondspx.com/2024/07/31/acasti-pharma-nasdaqacst-a-promising-specialty-pharmaceutical-company-focused-on-rare-and-orphan-diseases...
MikeTester - August 2, 2024

the perfect situation

With a market cap  trading  under the cash in the cie and 3 products in clinic phase announcing news in the coming weeks you...
bingostar - December 22, 2022

RE:GTX-104 positive results

No One is paying attention to them, look at the decline in share price, its hard to believe they are still around, glad I dumped when...
Canadian_101 - November 21, 2022

GTX-104 positive results

As annouced today:  Acasti Pharma Announces Positive Results for Pharmacokinetic Bridging Study, With Intravenous GTX-104 Meeting...
bingostar - May 18, 2022

Acasti Pharma to Present

LAVAL, Qubec, April 25, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today...
Betteryear2 - April 25, 2022

acasti

Credability at work.This stock has not yet met any significant forcast.Carepre was badly promoted and the real reason it failed has never...
alanmar1 - April 3, 2022
View more Bullboard ››

Osisko Development Corp.

Osisko Development Corp.

Osisko Development Corp. is a continental North American gold development company focused on past-producing mining camps ...
View More »

Podcasts